Mosunetuzumab generated durable responses in patients with highly refractory non-Hodgkin lymphomas.
Tanya Siddiqi, MD, discussed the CAR T-cell trial ahead of the ASH Annual Meeting & Exposition in an interview with CancerNetwork®.
Research on chimeric antigen receptor T-cell therapy to be presented at the ASH Annual Meeting & Exposition is set to address drawbacks associated with treatment.
Researchers compared the ability of a novel prognostic score vs existing scores to identify patients with high-risk DLBCL.
The results of a follow-up analysis to the phase III MAVORIC study were presented at the ASH 2018 Annual Meeting & Exposition.
Research presented at ASH 2018 examined whether checkpoint blockade therapy sensitizes patients with relapsed/refractory NHL to consequent treatment.
In the single-arm, multicenter, phase II part of the CAVALLI trial, the researchers analyzed the efficacy of 800-mg venetoclax plus R-CHOP in all first-line DLBCL patients.
Researchers developed an enhanced genomic model combining clinical factors and select gene mutations in order to better predict survival in patients with DLBCL who were administered first-line R-CHOP.
Researchers studied clonal hematopoiesis of indeterminate potential (CHIP) as a way to assess risk for increased mortality in lymphoma patients.
Adding rituximab to MBVP induction chemotherapy does not improve outcomes for patients with primary central nervous system lymphoma.